A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT ID: NCT06837233

Last Updated: 2025-05-25

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-12
• Study Completion Date: 2026-05-31

Brief Summary

The study is a multicenter, randomized, double-blind, placebo-controlled seamless and adaptive-designed phase IIb/III study encompassing a phase IIb and a phase III component. The phase IIb study, which is registered this time, is a dose-ranging component. The phase III study is a pivotal part of the overall research.

The goal of this phase IIb study is to evaluate the efficacy, safety, and pharmacokinetics of PG-011 nasal spray across various dosages and administration frequencies for treating adults with moderate to severe seasonal allergic rhinitis (SAR). Investigators will compare PG-011 nasal spray to a placebo (a look-alike substance that contains no drug) to see which dosage and frequency works to treat moderate to severe seasonal allergic rhinitis.

Detailed Description

This is a multicenter, randomized, double-blind, placebo-controlled clinical study in adults participants aged from 18 to 65 years old (including threshold) with moderate to severe SAR. Approximately 160 participants will be randomized assigned to one of the 4 following groups in a 1:1:1:1 ratio.

PG-011 nasal spray 0.3% ( 0.6mg Pumecitinib) administered twice daily, PG-011 nasal spray 0.6% (1.2mg Pumecitinib) administered once daily, PG-011 nasal spray 0.6% (1.2mg Pumecitinib) administered twice daily, PG-011 placebo nasal spray 0% (0 mg Pumecitinib) administered once or twice daily.

Participants will receive blinded study treatment for 14 days followed by 21 days safety follow-up.

Conditions

Seasonal Allergic Rhinitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

PG-011 nasal spray 0.3% (twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

Group Type: EXPERIMENTAL

Pumecitinib Nasal Spray 0.3%

Intervention Type: DRUG

2 sprays in each nostril, twice daily for 14-day treatment period.

PG-011 nasal spray 0.6%(once daily)

2 sprays in each nostril, once daily for 14-day treatment period.

Group Type: EXPERIMENTAL

Pumecitinib Nasal Spray 0.6%

Intervention Type: DRUG

2 sprays in each nostril, once daily for 14-day treatment period.

Placebo

Intervention Type: DRUG

2 sprays in each nostril, once daily for 14-day treatment period.

PG-011 nasal spray 0.6%(twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

Group Type: EXPERIMENTAL

Pumecitinib nasal spray 0.6%(twice daily)

Intervention Type: DRUG

2 sprays in each nostril, twice daily for 14-day treatment period.

Vehicle nasal spray(twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

Group Type: PLACEBO_COMPARATOR

Placebo (twice daily)

Intervention Type: DRUG

2 sprays in each nostril, twice daily for 14-day treatment period.

Interventions

Pumecitinib Nasal Spray 0.3%

2 sprays in each nostril, twice daily for 14-day treatment period.

Intervention Type: DRUG

Pumecitinib Nasal Spray 0.6%

2 sprays in each nostril, once daily for 14-day treatment period.

Intervention Type: DRUG

Placebo (twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

Intervention Type: DRUG

Pumecitinib nasal spray 0.6%(twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

Intervention Type: DRUG

Placebo

2 sprays in each nostril, once daily for 14-day treatment period.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female aged 18 to 65 (including threshold).

2. Reflective total nasal symptom score ( rTNSS) score≥ 6 and retrospective nasal obstruction ≥ 2 on the day of screening visit, D-4 and D1. Meanwhile, the baseline average rTNSS score(Calculated as the average of rTNSS score of D-3, D-2, D-1 morning, D-1 evening, and D1 morning) ≥ 6

3. History of SAR for at least 2 years. and positive results for any local allergen in the current season tested by either the skin prick test (SPT) (where the wheal diameter is at least 5 mm larger than that of the negative control) or the serum - specific IgE (sIgE) test (the sIgE test results obtained within ≤ 1 year before random enrollment are acceptable).

4. Willingness to avoid pregnancy or fathering children from the signing of the informed consent form until one month after the last administration of the investigational medicinal product.

5. Willing to sign the informed consent form and abide by the research protocol.

Exclusion Criteria

1. Participants are diagnosed of active or latent tuberculosis infection.

2. Participants are diagnosed of moderate to severe asthma.

3. Participants who had active pulmonary diseases or infections (including but not limited to bronchitis, pneumonia), upper respiratory tract infections or sinus infections within 4 weeks before screening, and/or those who had respiratory infections during the lead-in period.

4. Participants received nasal or sinus surgery within 3 months before screening or had nasal trauma that had not fully healed.

5. Any nasal mucosal erosion, nasal septal ulcer, nasal septal perforation or other nasal diseases that, as judged by the investigator, may affect the deposition of drugs in the intranasal, such as acute or chronic sinusitis, drug-induced rhinitis, nasal polyps, etc.

6. Participants has ocular herpes simplex or other ocular infections (except seasonal allergic conjunctivitis).

7. Participants with facial or systemic fungal, bacterial, viral or parasitic infections, or oral infections that had not been cured and still required continuous treatment within 4 weeks before screening.

8. Participants have severe diseases such as central nervous system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system or blood system, which may affect the judgment of efficacy and safety .

9. Participants who were infected with human immunodeficiency virus (HIV) at the time of screening, those in the active stage of hepatitis C virus (HCV) infection (anti - HCV positive), those in the active stage of hepatitis B virus (HBV) infection (HBV - DNA > 2000 IU/mL or 10⁴ copies/mL), or those with positive Treponema pallidum antibody indicating an active stage of infection.

10. Any drug treatments before lead-in period, such as use of nasal or systemic decongestants and anticholinergic drugs within 3 days, use of antihistamines such as cetirizine, fexofenadine, and loratadine within 5 days, systemic use of glucocorticoids within 4 weeks, or local use of glucocorticoids, mast cell stabilizers, tricyclic antidepressants, and leukotriene receptor antagonists within 2 weeks, and use of anti - allergic Chinese herbal medicines within 2 weeks.

11. During the trial, participants who cannot stop using JAK inhibitors, tricyclic antidepressants, glucocorticoids, decongestants, antihistamines (except loratadine, which is a rescue drug required during the treatment), leukotriene receptor antagonists, mast cell stabilizers (including sodium cromoglycate, nedocromil sodium, tetrazolium chromone, nedocromil sodium, pemirolast potassium, and tranilast, etc.), anticholinergic drugs, anti - allergic Chinese herbal medicines, and those who cannot stop using nasal irrigation.

12. Participants who have undergone desensitization therapy or received immunotherapy within 6 months prior to screening.

13. Participants who are known or judged by the investigator to potentially have an allergic reaction to the active ingredients or excipients of the investigational drug.

14. Participants who have a history of intolerance to intranasal administration.

15. Participants who plan to travel outside the local area for 2 consecutive days or more during the trial.

16. Participants who have participated in other clinical studies of investigational drugs or medical devices within 3 months prior to screening.

17. Participants who have a history of drug abuse or alcoholism within 1 year prior to screening

18. Female participants who are breastfeeding or pregnant at the time of screening

19. Reproductive - age participants (male or female) who plan to become pregnant, breastfeed, or donate sperm/eggs during the study or within 1 month after the study ends

20. Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for participation in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prime Gene Therapeutics Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Luo Zhang, Professor

Role: PRINCIPAL_INVESTIGATOR

Beijing Tongren Hospital

Locations

Beijing Shijitan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Beijing Youan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Cangzhou Central Hospital

Cangzhou, Hebei, China

Hebei Petro China Central Hospital

Langfang, Hebei, China

Luo Yang First People's Hospital

Luoyang, Henan, China

Zhengzhou Central Hospital

Zhengzhou, Henan, China

The Central Hospital of Wuhan

Wuhan, Hubei, China

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Baotou Central Hospital

Baotou, Neimenggu, China

Chifeng Municipal Hospital

Chifeng, Neimenggu, China

Shandong Second Provincial People's Hospital

Jinan, Shandong, China

Liaocheng People's Hospital

Liaocheng, Shandong, China

Yantai YuHuangDing Hospital

Yantai, Shandong, China

Zibo Central Hospital

Zibo, Shandong, China

Linfen Central Hospital

Linfen, Shanxi, China

Linfen People's Hospital

Linfen, Shanxi, China

First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

The First Affiliated Hospital of Xi'an Jiao Tong University

Xi’an, Shanxi, China

Yuncheng Central Hospital

Yuncheng, Shanxi, China

Countries

China

Other Identifiers

CTR20250489

Identifier Type: OTHER

Identifier Source: secondary_id

PG-011-SAR-301

Identifier Type: -

Identifier Source: org_study_id